Cancer Survival in Reunion Island , 1998-2008 (SUCRE) (SUCRE)

January 4, 2024 updated by: Centre Hospitalier Universitaire de la Réunion

Survie Des Personnes Atteintes de Cancer à la Réunion, 1998-2008 (SUCRE)

Cancer survival is important to determine prognostic of patients and evaluate care and prevention health strategies. Sucre is the first study to describe cancer survival in Reunion Island. Sucre aims at evaluating five year cancer prognostic in Reunion Island by cancer site and gender. Sucre is a retrospective cohort study of cancer diagnosed between 01/01/1998 and 31/12/2008.

Study Overview

Status

Completed

Conditions

Detailed Description

Data are extracted from Reunion Island Cancer Registry.

Study Type

Observational

Enrollment (Actual)

18000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Réunion
      • Saint-Denis, Réunion, 97400
        • CHU de la Réunion

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

15 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Study population extracted from Reunion Island Cancer Registry

Description

Inclusion Criteria:

  • Patients domiciled in Reunion Island at diagnosis
  • Patients with at least 15 years of age at diagnosis
  • Patients with cancer diagnosis between 01/01/1998 and 31/12/2008

Exclusion Criteria:

  • Cutaneous malignant cancer expected melanoma

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
5 years related survival rate by cancer site and gender
Time Frame: 5 years
5 years

Secondary Outcome Measures

Outcome Measure
Time Frame
1, 3, 5 and 10 years related survival rate by cancer site and gender
Time Frame: 1, 3, 5 and 10 years
1, 3, 5 and 10 years
1, 3, 5 and 10 years standardised survival rate by cancer site and gender
Time Frame: 1, 3, 5 and 10 years
1, 3, 5 and 10 years
1, 3, 5 and 10 years related survival rate by age at diagnosis
Time Frame: 1, 3, 5 and 10 years
1, 3, 5 and 10 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Centre Hospitalier Universitaire de la Réunion

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2019

Primary Completion (Actual)

December 31, 2019

Study Completion (Actual)

December 31, 2019

Study Registration Dates

First Submitted

September 9, 2016

First Submitted That Met QC Criteria

September 13, 2016

First Posted (Estimated)

September 14, 2016

Study Record Updates

Last Update Posted (Actual)

January 5, 2024

Last Update Submitted That Met QC Criteria

January 4, 2024

Last Verified

January 1, 2024

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 2014/CHU/05

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Neoplasms

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe